Please login to the form below

Not currently logged in
Email:
Password:

Minoyrx Therapeutics appoints chief medical officer

Dr Uwe Meya joins from Lupin Atlantis Holdings

Minoryx Therapeutics Dr Uwe MeyaSpanish orphan disease specialist Minoryx Therapeutics has appointed Dr Uwe Meya as its new chief medical officer.

Dr Meya brings over 30 years of research and development experience to the firm, with a background as a neurologist and psychiatrist.

He joins the Barcelona-based drug development company from Lupin Atlantis Holdings, where he oversaw its clinical strategy and implementation of studies in various therapeutic areas, including neurodegenerative disorders.

Prior to this, Dr Meya was head of phase I and II clinical studies in neurodegenerative disorders at Synosia Therapeutics, and served as head of research portfolio management and clinical research and licensing liaison manager in CNS at Roche.

He also has leadership experience working at Novartis in CNS clinical development, at Knoll as head of clinical development, and as a medical advisor and the head of clinical psychiatry at Schering.

Marc Martinell, chief executive officer of Minoryx Therapeutics, said: “We are delighted to welcome Dr Meya as our chief medical officer.

“Hi wealth of expertise in CNS-related research will help us significantly in moving forward the clinical development of our lead candidate MIN-102. He will also support the further development of our pipeline in orphan diseases.”

24th June 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...